DexTech Medical (DEX) Q1 2026 earnings summary

Executive summary

• No net sales were recorded for the quarter; operations focused on ongoing clinical studies and R&D activities.

• Operating loss was MSEK -1.3, unchanged from the same quarter last year, with earnings per share at SEK -0.07.

• The myeloma phase 1 study with OsteoDex showed promising interim results, with 67% of patients in dose group 2 responding positively and no significant side effects.

• The Data Monitoring Committee approved progression to the highest dose group in the myeloma study.

Financial highlights

• Net sales were MSEK 0.0, unchanged year-over-year.

• Operating profit/loss was MSEK -1.3, same as the previous year.

• Profit after tax was MSEK -1.3, compared to MSEK -1.1 last year.

• Cash and cash equivalents at period end were MSEK 14.1, down from MSEK 14.7 a year ago.

• Equity at period end was MSEK 23.5, with an equity/assets ratio of 97%.

Outlook and guidance

• Operations are funded through equity, with sufficient working capital secured until the end of 2026.

• The goal is to finance future operations through license revenues after 2026.

• The ongoing phase 1 myeloma study is expected to complete in Q4 2025.